Overview
Employees
11-50
Total raised
$35M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 15, 2009 | Cancer drug maker BiPar sells to Sanofi-aventis for $500M | BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divid... |
| Jan 13, 2009 | BiPar snags $20M for inhibitor-based cancer therapies | Pharmaceutical firm BiPar Sciences just brought in $20 million in private equity and venture debt to advance its lead therapy, targeting breast cancer, to phase-three clinical trials. The investment will double the Brisbane, Calif.-based co... |
| Sep 19, 2007 | Life sciences briefing: Wednesday, Sept. 19, 2007 | Featured companies: Acceleron Pharma, AdvanDx, Altheus Therapeutics, BiPar Sciences, Coventina Healthcare Enterprises, ForteBio, Ganymed Pharmaceuticals, Mako Surgical, Nile Therapeutics, Novate Medical [NOTE: This briefing was posted on Fr... |
| Feb 27, 2007 | BiPar Sciences raises $35M for cancer therapies | BiPar Sciences, Inc., a biopharmaceutical company developing cancer therapies, said it has raised $35 million in a second round of financing. The round was led by Domain Associates. Existing investors participated, including Vulcan Capital,... |
| Domain Associates closes $500 million life science fund | PRINCETON, New Jersey — Venture fund Domain Associates has closed a $500 million fund to invest in early-stage drug and medical device companies with “meaningful portion of its efforts going towards the diagnostics and instrumentation secto... |